NEW YORK (GenomeWeb) – Sequenom reported after the close of the market Thursday that its first quarter revenues climbed 20 percent compared to the first quarter of 2013, driven by its diagnostics business, including sales of its MaterniT21 Plus noninvasive prenatal test for fetal aneuploidy.

The San Diego-based molecular diagnostics firm reported total Q1 revenues of $46.3 million, compared to $38.5 million in the first quarter 2013. Revenues were slightly above the Wall Street consensus estimate.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.